Kevin Kunzmann

The NeuralBot assists clinicians in non-invasive monitor of patient brain blood flow characteristics, and provides diagnostic information for a variety of neurological disorders.

The investigative monoclonal antibody has more data backing its efficacy, safety, and tolerability across 2 dose regimens.

The solution from Sage Therapeutics may become the first treatment indicated for women with postpartum depression.

The NDA for the investigative long-acting subcutaneous buprenorphine injection was turned down in lieu of more data in January.

The T2Bacterial Panel has proven able to detect specific sepsis-causing bacterial pathogens nearly 10 times faster than competitors.

The single-use triple-therapy device has proven significantly more easily managed by patients in a crossover study.

When inhaled, cinnamaldehyde can disrupt the lung's anti-bacterial defense system, exposing users to respiratory infection.

Increasing particulate matter and ozone rates, even in lower-pollution regions, is putting the elderly at risk of acute respiratory distress syndrome.

The longtime therapy Symbicort was tested for safety and efficacy versus SABA in 8000-plus patients on an as-needed treatment basis.

The administration of the treatment to asthma patients is fairly common, despite guidelines advocating against it under certain circumstances.

Sanofi and Regeneron reported promising results from a pair of pivotal phase 3 trials for the investigative add-on therapy.

From food deserts to hazardous jobs that inhibit exposure and limit the means to prevent it, people of low SES are at greatest environmental health risk.

Researchers intend to follow observed infants into early childhood to gauge the vitamin's influence on pediatric asthma rates.

Children given immunocap radioallergosorbent tests when hospitalized for asthma avoided re-hopsitalization twice as long as children not given the test.

The inhaled corticosteroid from GSK is indicated for pediatric asthma patients aged 5-11 years old.

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

The monoclonal antibody reported quick and consistent exacerbation rate reduction in patients with severe eosinophilic asthma.

The once-daily, triple-drug inhaler therapy reported improvements in exacerbation rate and risk to first event.

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

The therapy showed reduction in nighttime resting heart rate comparable to that of beta blockers.

The FDA had issued a Class I recall of the MindFrame Capture LP device.

CGRP inhibitor therapies have shown long-term efficacy, safety, and tolerability profiles at the clinical stages — and erenumab is just the first of them to reach the market.

The 625 mg tablet Welchol was first approved for cholesterol and/or glycemic management by the FDA in 2000.

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

Medic Vision's iQMR reported 30% reduced brain exam scan time without adverse effects to image quality.

Roche's cobas test systems will now be able to screen multiple individual blood or plasma donations that have been pooled together.

The injection therapy was a previously non-approved FDA product that was grandfathered into marketed use for about 4 decades.

The rate shows a correlated effect on the collaboration efforts between nurses and physicians.

Fingolimod was first approved for adult patients with the relapsing form of MS, and was granted Priority Review and Breakthrough Therapy designation in December.

TLANDO is being investigated for the treatment of adult men with deficiencies of endogenous testosterone.